AB1509 MUCOCUTANEOUS INVOLVEMENT IS THE MORE FREQUENT REASON FOR IMMUNOSUPPRESSIVE NEED COMPARED TO MAJOR ORGAN INVOLVEMENT IN AN EARLY MALE BEHÇET’S DISEASE PROSPECTIVE COHORT

Background Major organ involvement is one of the main causes mortality and morbidity in Behçet’s Disease (BD) [1]. However, prognosis predictors major are insufficiently studied. Objectives We aimed to follow young, male BD patients with only mucocutaneous symptoms who have highest risk for new prospectively. Methods Thirty-six were included study. Patients assessed prospectively at 3-6 months intervals any urgent visits. New involvements reasons immunosuppressive (IS) need during prospective follow-up. Results At baseline, mean disease duration was 3.3 years. All under colchicine treatment. The follow-up 90.7 months. Overall, 13 (36.1%) needed IS therapy reason 5 (13.9%), refractory 7 (19.4%), articular 1 (2.8%) (Table 1, Figure ). vascular 3 patients, ocular patient, patient. In 8 these step-up treatment ISs due or relapse. Conclusion Our study demonstrated a lower incidence events compared retrospective cohorts literature. results showed that more frequent than Reference [1]Alibaz-Oner F, Direskeneli H. Management disease. Int J Rheum Dis. 2019;22 Suppl 1:105-8. Table 1. Clinical characteristics Reason use Age Diagnosis when started agent Patient Pulmonary aneurysm 35 year Azathioprine 2 Refractory OU 25 years Cyclosporine Deep venous thrombosis 38 10 4 Uveitis 20 28 6 23 EN 9 Arthritis Methotrexate 29 11 EN+ Articular Involvement 12 Superficial Thrombophlebitis IS: Immunosuppressive, OU: Oral ulcer, EN: erythema nodosum immunosupressive Behçet (n) Acknowledgements I no acknowledgments declare. Disclosure Interests None Declared.